What smart money is saying about Roivant Sciences
1 fund in our archive has pitched Roivant Sciences, most recently Baron Health Care Fund in September 2025.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Get an email when a fund buys, sells or pitches it
Position history
Between Q3 2025 and Q2 2026, 2 fund letters reported a position in Roivant Sciences, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 1 | 0 | 1 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 1 move
- June 2026
Listed in Baron Health Care Fund’s reported holdings.
Roivant Sciences - ExitedTourlite CapitalDecember 2025
“In hindsight, part of the underperformance stemmed from recycling positions too early. APi Group in the fourth quarter of 2024 and Roivant in the middle of this year are notable examples.”
Roivant Sciences
Fund coverage · 1 thesis
- Baron Health Care FundSeptember 2025
Roivant Sciences Ltd. is a biotechnology company that develops focused subsidiaries called "Vants" to create pipeline drugs, with promising prospects for significant upside based on recent successes and ongoing projects.
Read the full thesis
Read every full thesis on Roivant Sciences
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→